Ceribell To Participate In The Canaccord Genuity Medtech, Diagnostics And Digital Health & Services Forum
Event: Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum
Date: Wednesday, November 11, 2026
Time: 7:00 a.m. PST / 10:00 a.m. EST
A live and archived webcast of the fireside chat will be available in the "Investor Relations" section of the Ceribell website at .
About CeriBell, Inc.
Ceribell is a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. Ceribell has developed the Ceribell System, a novel point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute-care setting. By combining proprietary, highly portable, and rapidly deployable hardware with sophisticated artificial intelligence (“AI”)-powered algorithms, the Ceribell System enables rapid diagnosis and continuous monitoring of patients with neurological conditions. The Ceribell System is FDA-cleared for use in detecting seizure and monitoring delirium in intensive care units and emergency rooms across the U.S. Ceribell is headquartered in Sunnyvale, California. For more information, please visit or follow the company on LinkedIn.
Investor Contact
Brian Johnston
Gilmartin Group
...
Media Contact
Laura Hartlieb
...
Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept
any responsibility or liability for the accuracy, content, images,
videos, licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright
issues related to this article, kindly contact the provider above.
Comments
No comment